NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a discussion with Liz Barrett, Global President, Oncology, and Chris Boshoff, Senior Vice President and Head, Immuno-Oncology, Early Development and Translational Oncology, at the LEERINK Partners Roundtable Series: Rare Disease and Immuno-Oncology on Thursday, September 28, 2017 at 9:00 a.m. Eastern Daylight Time.
Visitors will be able to listen to an archived copy of the webcast at www.pfizer.com/investors.
Disclosure Notice: The webcast may include forward-looking statements about, among other things, our anticipated future operating and financial performance, business plans and prospects, in-line products and product candidates, strategic reviews, capital allocation, business-development plans, the benefits expected from our business development transactions and plans relating to share repurchases and dividends that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. A description of these risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
The forward-looking statements in the webcast speak only as of the original date of the webcast. Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.